Dimethazan
|  | |
|  | |
| Clinical data | |
|---|---|
| Routes of administration | Oral | 
| ATC code | none | 
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| 
 | |
| Synonyms | 1,3-dimethyl-7-(2-dimethylaminoethyl)xanthine; 7-(2-dimethylaminoethyl)theophylline | 
| CAS Number | 519-30-2 | 
| PubChem (CID) | 10612 | 
| ChemSpider | 10167 | 
| UNII | H943V308AD  Y | 
| ECHA InfoCard | 100.007.516 | 
| Chemical and physical data | |
| Formula | C11H17N5O2 | 
| Molar mass | 251.29 g/mol | 
| 3D model (Jmol) | Interactive image | 
| 
 | |
Dimethazan (Elidin) is a stimulant drug of the xanthine class related to caffeine and theophylline.[1] It also has tranquilizing and respiratory-stimulating effects and has been sold as an antidepressant.[1][2]
See also
References
- 1 2 BATTERMAN RC, GROSSMAN AJ, LEIFER P, MOURATOFF GJ (August 1958). "Central nervous system stimulation and sedation with dimethazan". The American Journal of the Medical Sciences. 236 (2): 162–7. PMID 13559232.
- ↑ O'Neil, Maryadele J. (2001). The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Rahway, NJ: Merck Research Laboratories. ISBN 0-911910-13-1.
| 
 | |||||||||||||||||||||||||||||||||||||
| 
 | |||||||||||||||||||||||||||||||||||||
| 
 | |||||||||||||||||||||||||||||||||||||
| 
 | |||||||||||||||||||||||||||||||||||||
| Stimulants (category) | |
|---|---|
| Adamantanes | 
 | 
| Adenosine antagonists | |
| Alkylamines | |
| Ampakines | |
| Arylcyclohexylamines | |
| Benzazepines | |
| Cholinergics | 
 | 
| Convulsants | |
| Eugeroics | |
| Oxazolines | |
| Phenethylamines | 
 | 
| Phenylmorpholines | |
| Piperazines | |
| Piperidines | 
 | 
| Pyrrolidines | |
| Racetams | |
| Tropanes | 
 | 
| Tryptamines | |
| Others | 
 | 
| Receptor (ligands) | 
 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (blockers) | 
 | ||||||||||||||||
| Enzyme (inhibitors) | 
 | ||||||||||||||||
| Others | |||||||||||||||||
This article is issued from Wikipedia - version of the 5/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.